GlassScriptPhysician profile
Joena R Chan
NPI 1760420970
$18,808.18
in general payments reported to CMS, 2019-2025
49 companies · $3,153 in 2025
The $3,153 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,203 · 2020: $1,895 · 2021: $2,705 · 2022: $2,867 · 2023: $3,387 · 2024: $3,598 · 2025: $3,153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,137.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,416.18 | 2019-2025 | Ubrelvy, Qulipta, Vraylar |
| Astrazeneca Pharmaceuticals LP | $2,408.79 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $2,038.57 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,847.55 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $1,434.62 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $1,356.05 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,021.88 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| E.R. Squibb & Sons, L.L.C. | $798.33 | 2019-2025 | Eliquis, Camzyos |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $564.35 | 2019-2024 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $467.21 | 2019-2025 | Lagevrio, Gardasil 9, Capvaxive |
| Janssen Pharmaceuticals, INC | $431.23 | 2019-2024 | Xarelto |
| Abbott Laboratories | $353.21 | 2022-2025 | Freestyle Libre |
| Amarin Pharma, INC. | $266.15 | 2019-2022 | |
| Exact Sciences Corporation | $249.08 | 2023-2025 | Cologuard Collection Kit |
| Allergan, INC. | $191.63 | 2019-2020 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joena Chan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.